November 30, 2021 Go or no go? Argenx's December showdown 2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
January 15, 2018 Tide turns as 2017 IPOs ramp up Biotechs raised $3.9bn in IPOs across 2017, signalling that investor interest in new issues has returned.